CollPlant Biotechnologies’ (CLGN) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a research note released on Wednesday,Benzinga reports. They currently have a $14.00 target price on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of CollPlant Biotechnologies in a research report on Friday, November 29th.

CollPlant Biotechnologies Price Performance

Shares of CollPlant Biotechnologies stock opened at $3.60 on Wednesday. The stock has a market cap of $41.22 million, a P/E ratio of -2.34 and a beta of 0.86. The stock’s 50 day simple moving average is $3.83 and its 200-day simple moving average is $4.28. CollPlant Biotechnologies has a 1-year low of $3.24 and a 1-year high of $6.75.

CollPlant Biotechnologies (NASDAQ:CLGN) last released its quarterly earnings data on Wednesday, November 27th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). CollPlant Biotechnologies had a negative net margin of 2,680.00% and a negative return on equity of 77.05%. During the same period last year, the firm earned ($0.38) earnings per share. As a group, research analysts expect that CollPlant Biotechnologies will post -1.44 EPS for the current fiscal year.

Hedge Funds Weigh In On CollPlant Biotechnologies

Several large investors have recently bought and sold shares of the business. Renaissance Technologies LLC purchased a new position in CollPlant Biotechnologies in the fourth quarter valued at $38,000. Wells Fargo & Company MN boosted its stake in CollPlant Biotechnologies by 110.1% in the fourth quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock valued at $30,000 after acquiring an additional 4,405 shares in the last quarter. AMH Equity Ltd boosted its stake in CollPlant Biotechnologies by 17.4% in the fourth quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock valued at $419,000 after acquiring an additional 17,295 shares in the last quarter. Benjamin Edwards Inc. acquired a new position in CollPlant Biotechnologies in the third quarter valued at $112,000. Finally, Villere ST Denis J & Co. LLC boosted its stake in CollPlant Biotechnologies by 24.4% in the third quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock valued at $2,407,000 after acquiring an additional 95,000 shares in the last quarter. Hedge funds and other institutional investors own 21.69% of the company’s stock.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.